Advances in Multiple Myeloma

Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood cell normally responsible for producing antibodies. Initially, there are often no symptoms. When advanced, bone pain, bleeding, frequent infections, and anemia may occur. Complications may include amyloidosis. The cause is generally unknown. The underlying mechanism involves abnormal plasma cells producing abnormal antibodies which can cause kidney problems and overly thick blood. The plasma cells can also form a mass in the bone marrow or soft tissue. When there is only one mass it is known as a plasmacytoma and when there is more than one it is known as multiple myeloma. Multiple myeloma is diagnosed based on blood or urine tests finding abnormal antibodies, bone marrow biopsy finding cancerous plasma cells, and medical imaging finding bone lesions. Multiple myeloma is considered treatable but generally incurable. Remissions may be brought about with steroids, chemotherapy, thalidomide or lenalidomide, and stem cell transplant. Bisphosphonates and radiation therapy are sometimes used to reduce pain from bone lesions.


In the present book, fifteen typical literatures about multiple myeloma published on international authoritative journals were selected to introduce the worldwide newest progress, which contains reviews or original researches on medical science, hematology, Lymphatic diseases, osteosarcoma, ect. We hope this book can demonstrate advances in multiple myeloma as well as give references to the researchers, students and other related people.
Components of the Book:
  • Chapter 1
    A Case of Multiple Myeloma in a Poultry Worker
  • Chapter 2
    A Case of Bilateral Pleural Effusion as the First Sign of Multiple Myeloma
  • Chapter 3
    Epigenetic Silencing of a Long Non-Coding RNA KIAA0495 in Multiple Myeloma
  • Chapter 4
    Establishment of a Bortezomib-Resistant Chinese Human Multiple Myeloma Cell Line: MMLAL
  • Chapter 5
    A Case of Multiple Myeloma Presenting as a Distal Renal Tubular Acidosis with Extensive Bilateral Nephrolithiasis
  • Chapter 6
    High Applicability of ASO-RQPCR for Detection of Minimal Residual Disease in Multiple Myeloma by Entirely Patient-Specific Primers/Probes
  • Chapter 7
    Heat Shock Factor 1 Is a Potent Therapeutic Target for Enhancing the Efficacy of Treatments for Multiple Myeloma with Adverse Prognosis
  • Chapter 8
    Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
  • Chapter 9
    Predicting Poor Peripheral Blood Stem Cell Collection in Patients with Multiple Myeloma Receiving Pre-Transplant Induction Therapy with Novel Agents and Mobilized with Cyclophosphamide Plus Granulocyte-Colony Stimulating Factor: Results from a Gruppo Italiano Malattie EMatologiche Dell’Adulto Multiple Myeloma Working Party Study
  • Chapter 10
    Recurrent Extramedullary Plasmacytoma in Asymptomatic Multiple Myeloma: A Case Report
  • Chapter 11
    Managing Neutropenia by Pegfilgrastim in Patients Affected by Relapsed/Refractory Multiple Myeloma Treated with Bendamustine-Bortezomib-Dexamethasone
  • Chapter 12
    Pooled Analysis of the Reports of Carfilzomib, Panobinostat, and Elotuzumab Combinations in Patients with Refractory/Relapsed Multiple Myeloma
  • Chapter 13
    The Non-Peptide Thrombopoietin Receptor Agonist Eltrombopag Stimulates Megakaryopoiesis in Bone Marrow Cells from Patients with Relapsed Multiple Myeloma
  • Chapter 14
    Rationale and Design of the German-Speaking Myeloma Multicenter Group (GMMG) Trial ReLApsE: A Randomized, Open, Multicenter Phase III Trial of Lenalidomide/Dexamethasone versus Lenalidomide/Dexamethasone plus Subsequent Autologous Stem Cell Transplantation and Lenalidomide Maintenance in Patients with Relapsed Multiple Myeloma
  • Chapter 15
    Severe Resistant Hypocalcemia in Multiple Myeloma after Zoledronic Acid Administration: A Case Report
Readership: Students, academics, teachers and other people attending or interested in Multiple Myeloma.
Chor Sang Chim, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road, Pokfulam, Hong Kong.

Brigitte Sola, Normandie Univ, UNICAEN, EA4652, Caen, France.

Kenneth H. Shain, Department of Oncologic Sciences, Moffitt Cancer Center/University of South Florida Morsani College of Medicine,Tampa, FL, USA.

Pellegrino Musto, Scientific Direction, IRCCS, Referral Cancer Centre of Basilicata, Rionero in Vulture, PZ, Italy.

Saskia E. M. Schols, Department of Hematology, Internal Medicine, Maastricht University Medical Center, Debyelaan 25, 6229 HX Maastricht, The Netherlands.

Jee-Yeong Jeong, 1 Division of Hematology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA.

and more...
This Book

337pp. Published February 2017

Scientific Research Publishing, Inc.,USA.

Category:Biomedical & Life Sciences

ISBN: 978-1-61896-310-9

(Hardcover) USD 109.00

ISBN: 978-1-61896-309-3

(Paperback) USD 89.00

Authors/Editors Price: 40% off
Buy at: bookorder@scirp.org
Follow SCIRP
Contact us
book@scirp.org
WhatsApp +86 18163351462(WhatsApp)
Click here to send a message to me 1243940697
Book Publishing WeChat
Copyright © 2006-2024 Scientific Research Publishing Inc. All Rights Reserved.
Top